More information
Portrait Frank Buchholz

© CRTD

Sequencing of whole genomes has provided new perspectives into the blueprints of diverse organisms and has identified many disease causing alterations. Our laboratory is using different strategies to dissect and correct gene function in mammalian cells.

Advanced genome engineering

The need for fluent and precise genomic manipulation strategies has been exacerbated by the increasing pace of published genome sequences. Beyond the reading of complete genomes, the precise manipulation of the encoded information is becoming more important in modern molecular biology as well as personalized medicine. The field of safe and precise genome editing provides a genuine opportunity to establish innovative approaches to repair DNA mutations to replace, engineer or regenerate malfunctioning cells in vitro or in vivo.

Site specific recombinases are prominent genetic engineering tools that allow an efficient and specific genetic manipulation of whole organisms. In order to expand the usefulness of these enzymes we are developing Designer-recombinases through directed molecular evolution and deep learning-based protein engineering.

Furthermore, we apply the CRISPR technologies to dissect cancer mutations and use sophisticated functional genomics tools (esiRNA and CRISPR screens) to identify cancer cell vulnerabilities. By combining our knowhow in genome editing and functional genomics, we aim at improving cancer patient diagnostics and therapy.

Frank Buchholz Research: Figure
Figure: Model of a designer recombinase excising the HIV-1 provirus from an infected cell.

Future Projects and Goals

  • Develop and apply tools that allow flexible and precise genomic manipulations
  • Apply CRISPR/Cas9 system to functionally dissect cancer mutation at large scale using cancer cell lines and cancer organoids
  • Perform large scale RNAi/CRISPR screens in cell lines and primary human cells (organoids) to identify and characterize factors implicated in cellular transformation
  • Perform phenotypic profiling in primary human cells to identify and characterize candidate genes with therapeutic potential

Methodological and Technical Expertise

  • Site-specific recombination
  • Directed molecular evolution
  • CRISPR/Cas9 technology
  • Long read PacBio sequencing
  • Nanopore sequencing
  • Large scale RNAi/CRISPR screens
  • BAC-tagging
  • Live cell microscopy
  • Organoid culture
  • Deep-Learning/KI

Currently Recruiting

Frank Buchholz is recruiting in the PhD Spring Selection 2025 (call is closed)

Open Project
  • Development and validation of genome editing tools for therapeutic treatment
    Preferred Course of Study/Expertise of Candidate: Molecular Biology, Cell Biology, Gene Editing

CV

Since 2022
Dean of Research at the Faculty of Medicine Carl Gustav Carus, TU Dresden

Since 2010
W3 Professor for Medical Systems Biology at the Faculty of Medicine Carl Gustav Carus and University Hospital Carl Gustav Carus, TU Dresden

2001–2010
Group Leader at the Max Planck Institute of Molecular Cell Biology and Genetics

1998–2000
Post-doctoral training at the University of California San Francisco (UCSF), the G.W. Hooper Foundation

1997
PhD in Biology, EMBL, Heidelberg

More Information

www.buchholzlab.org

Selected Publications

Schmitt LT, Schneider A, Posorski J, Lansing F, Jelicic M, Jain M, Sayed S, Buchholz F, Sürün D
Quantification of evolved DNA-editing enzymes at scale with DEQSeq
Genome Biol. 24(1):254 doi: 10.1186/s13059-023-03097-3 (2023)

Rojo-Romanos T, Karpinski J, Millen S, Beschorner N, Simon F, Paszkowski-Rogacz M, Lansing F, Schneider PM, Sonntag J, Hauber J, Thoma-Kress AK, Buchholz F
Precise excision of HTLV-1 provirus with a designer-recombinase
Mol Ther. S1525–0016(23)00135–1. doi: 10.1016/j.ymthe.2023.03.014 (2023)

Sayed S, Sidorova OA, Hennig A, Augsburg M, Cortes Vesga CP, Abohawya M, Schmitt LT, Sürün D, Stange DE, Mircetic J, Buchholz F
Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing
Cancer Res. can.21.2519. doi: 10.1158/0008-5472.CAN-21-2519 (2022)

Lansing F, Mukhametzyanova L, Rojo-Romanos T, Iwasawa K, Kimura M, Paszkowski-Rogacz M, Karpinski J, Grass T, Sonntag J, Schneider PM, Günes C, Hoersten J, Schmitt LT, Rodriguez-Muela N, Knöfler R, Takebe T & Buchholz F
Correction of a Factor VIII genomic inversion with designer-recombinases
Nature Communications 13:422 doi: 10.1038/s41467-022-28080-7 (2022)

Hoersten J, Ruiz-Gómez G, Lansing F, Rojo-Romanos T, Schmitt LT, Sonntag J, Pisabarro MT, Buchholz F
Pairing of single mutations yields obligate Cre-type site-specific recombinases
Nucleic Acids Res. gkab1240. doi: 10.1093/nar/gkab1240 Online ahead of print. PMID: 34951450 (2021)

Contact

University Hospital Carl Gustav Carus
Technische Universität Dresden
Fetscherstraße 74
01307 Dresden